Report updated Apr 17, 2026
epocrates: Drug Info & Pill ID
For u.S.-based healthcare professionals including physicians (MDs/DOs), nurse practitioners, physician associates, pharmacists, and medical students.
epocrates: Drug Info & Pill ID is a challenged medical app that is free with in-app purchases. With a 3.0/5 rating from 33.4K reviews, it faces significant user friction. Users particularly appreciate clinical utility, though aggressive monetization remains a common concern.
What is epocrates: Drug Info & Pill ID?
Current Momentum
v26.4 · 1w ago
MaintenanceThe app is currently in maintenance mode, with the most recent updates limited to general bug fixes and performance improvements.
Active Nemesis
MDCalc Medical Calculator
By MD Aware
Other Rivals
7-Day Rank Pulse 🇺🇸
MedicalNo ranking data
Rating Pulse 🇺🇸
Recent User Mood
What makes this app unique?
What Does It Look Like?
What Are The Key Features?
Simultaneously check interactions for up to 30 medications
Visual tool to identify pills by imprint, shape, color, or image
Full functionality available without internet connectivity
How much does it cost?
- Free base version with core clinical tools
- Premium upgrade (Epocrates+) via in-app purchase
The app has recently moved toward aggressive gating of core drug data, limiting free users to as few as 1-2 views per week, which is driving significant negative sentiment among long-term professional users.
Who Built It?
Providing U.S. healthcare professionals with point-of-care clinical decision support tools to improve prescribing safety and efficiency.
Portfolio
1
Apps
Explore the full Epocrates report
Portfolio breakdown, audience, momentum, and every app published by Epocrates.
What do users think recently?
High confidence · Latest 100 of 119 total reviews analyzed · Based on 119 reviews. Signal may be noisy.
How did the latest release land?
What is the recent mood?
Recent user voice shows a frustrated sentiment. Users appreciate clinical utility, but report aggressive monetization and critical stability issues.
What Users Love
What Frustrates Users
View the full user-sentiment analysis
Mood gauge, ratings & review-volume history, every praise / complaint / request, and sentiment over time.
What is the competitive landscape for epocrates: Drug Info & Pill ID?
How's The Medical Market?
How does it evolve in the Medical market?
Rank progression
1 active ranking tracked — 30-day window
The rivals identified
The outtake for epocrates: Drug Info & Pill ID
Strengths to defend, gaps to attack
Core Strengths
- Market-leading brand with 2M+ prescribers
- Unique 30-drug interaction checker and visual Pill ID
- Full offline database functionality
Critical Frictions
- Critical crashing bugs in v26.4.0 (iOS)
- Severe Android performance gap (2.65 rating)
- Restrictive 'free view' limits on core drug data
Growth Levers
- Add evidence-based summaries to calculators to match MDCalc
- Integrate patient education materials to compete with UpToDate
- Develop visual case-sharing features to counter Figure 1
Market Threats
- User migration to free resources like Merck Manual
- Competitors offering superior UX for clinical formulas (MDCalc)
- Loss of legacy professional users due to monetization shifts
What are the next best moves?
Immediate Hotfix for iOS v26.4.0
Top complaint theme is 'Critical Stability Issues' where the app crashes on load, rendering it unusable for clinicians.
Re-evaluate 'Free View' Limits
Sentiment data shows a 'declining' trend driven by users abandoning the app after being limited to 1-2 drug views per week.
Enhance Calculator Evidence
Competitor MDCalc wins on providing 'Next Steps' and PubMed links for every calculation, a feature gap in the current epocrates offering.
Feature Gaps vs Competitors
- Evidence-based clinical decision rules and PubMed links (available in MDCalc)
- Patient education materials (available in UpToDate)
- Visual/case-based crowdsourced learning (available in Figure 1)
- Procedural videos and 3D anatomical models (available in Merck Manual)
Key Takeaways
epocrates remains a revenue powerhouse as the #1 Grossing medical app, but it is currently burning user trust through a combination of critical stability failures and an overly restrictive paywall. To maintain its market lead, the PM must prioritize technical reliability and find a monetization balance that doesn't block the core utility of drug lookups for daily clinical practice.
Where Is It Heading?
Declining
v26.4.0 update causing immediate crashes on iOS — critical stability failure for point-of-care tool.
Upset user base due to new 'free view' limits — high risk of churn to free alternatives.
Recent updates focused on maintenance rather than feature expansion, while competitors like Figure 1 are innovating in case-based learning.